Study of nateglinide in Japan: Long-term treatment of patients with type 2 diabetes

Advances in Therapy

Volumn 23, Issue 2, 2006, Pages 307-324

  Taki, Hiroto ^a   Maki, Toshio ^a   Iso, Takako ^b   Iwamoto, Kenji ^b   Kajiura, Taiichi ^b  

^a AJINOMOTO CO INC   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Adverse reactions; Clinical efficacy; Long term use; Nateglinide; Postmarketing surveillance study; Postprandial hyperglycemia; Safety and adverse effect analyses

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN SENSITIZING AGENT; NATEGLINIDE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANOREXIA; ARTICLE; BODY MASS; CHOLANGITIS; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONSTIPATION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DYSPEPSIA; ECZEMA; EDEMA; EROSIVE GASTRITIS; ESOPHAGITIS; FEMALE; FLUSHING; GLUCOSE BLOOD LEVEL; HEADACHE; HEART PALPITATION; HEMOPTYSIS; HUMAN; HYPERHIDROSIS; HYPERURICEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOSMIA; INSULIN SYNTHESIS; JAPAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; PRURITUS; RASH; REFLUX ESOPHAGITIS; SIDE EFFECT; STOMACH DISCOMFORT; STOMACH ULCER; THORAX PAIN; TRIACYLGLYCEROL BLOOD LEVEL; URINARY FREQUENCY; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AGED; BLOOD GLUCOSE; CHOLESTEROL; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHENYLALANINE; PRODUCT SURVEILLANCE, POSTMARKETING; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES;

EID: 33745036562     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850136     Document Type: Article

References (13)

1. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Lancet. 1999; 354:617-621.
2. Kosaka K, Urae A, Amamoto T, Gonsho A, Kato N. A phase I study of AY4166 in healthy male volunteers-single oral administration in fasting state. Clin Pharm Ther. 1997;7:585-599.
3. Kosaka K, Urae A, Amamoto T, Gonsho A, Kato N. A phase I study of AY4166 in healthy male volunteers-repeated administration. Clin Pharm Ther. 1997;7:601-614.
4. Shigeta Y, Kuzuya K, Oomori Y, Ohashi Y, Kosaka K. Phase-III study of a novel hypoglycemic agent, AY4166, on NIDDM patients in Japan: placebo-controlled multicenter double-blind study. Clin Pharm Ther. 1997;7:729-754.
5. Taki H, Maki T, Iso T, et al. Postmarketing surveillance study of nateglinide in Japan. Adv Ther. 2005;22:513-526.
6. Taki H, Maki T, Iso T, et al. Postmarketing study of nateglinide in Japan: treatment of medication-naïve patients with type 2 diabetes. Adv Ther. 2005;22:621-635.
7. Mine T, Miura K, Kitahara Y, Okano A, Kawamori R. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and goto-kakizaki rats: comparison with voglibose and glibenclamide. Biol Pharma Bull. 2002;25:1412-1416.
8. Mori Y, Kitahara Y, Miura K, Tajima N. Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading. Endocrine. 2004;23:39-43.
9. Dimitriadis G, Boutati E, Lambadiari V, et al. Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism. Eur J Clin Invest. 2004;34:490-497.
10. Schatz H, Schoppel K, Lehwalder D, Schandry R. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions. Exp Clin Endocrinol Diabetes. 2003;111:262-266.
11. Kosaka K, Kikuchi M, Tarui S, et al. Effect of oral hypoglycemic drug AY4166 in long-term study with non-insulin-dependent diabetes mellitus (NIDDM). Clin Pharm Ther. 1997;7:797-818.
12. Kuzuya T, Oka Y, Yaga K, Inoue Y, Matsutani A, Kosaka K. Clinical evaluation of oral hypoglycemic drug AY4166 in long-term treatment with non-insulin-dependent diabetes mellitus (NIDDM). Clin Pharm Ther. 1997;7:819-832.
13. 1c lowering over 52 weeks in drug-naïve type 2 diabetes patients. Diabetologia. 2001;44:A215.